Blackwater fever was typically reported after quinine administration, although it is poor recognized in patients receiving artesunate. This case describes a blackwater fever in a non-immune patient after artesunate for severe malaria. It highlights the importance of monitoring haemolytic parameters in severe malaria to avoid renal impairment or severe anaemia.
Background
Blackwater fever is defined as an early intravascular haemolysis associated with marked haemoglobinuria and occasionally renal injury, jaundice and fever in patients with malaria. It was a condition typically reported after the administration of a few doses of quinine for malaria treatment in non-immune patients living in Africa, classically associated with low parasitemia;
1 it has been also described in immune population. 2 With the introduction of other drugs but quinine in the treatment of malaria, the incidence of blackwater fever has decreased. 3 It occurred in <10% of the participants in the artesunate arm in AQUAMAT and SEAQUAMAT studies, but without significant differences with quinine. 4, 5 A different scenario is delayed haemolysis associated to artesunate, usually presented between Days 7 and 21 after the start of the treatment; it has been described in up to 25% of cases in some studies. 6 In this cases, haemolysis is probably caused by a delayed clearance of pitting erythrocytes. 6 The present case report describes a blackwater fever syndrome in a non-immune patient early after treatment with intravenous artesunate for severe Plasmodium falciparum malaria.
and generalized arthralgia and myalgia after a trip to Guinea Conakri 10 days before symptoms started (September 2016).
The patient had stayed in Conakri city for 6 months. He never took malaria prophylaxis and he did not travelled to rural areas. As a medical record the patient had suffered from right retinal detachment associated to lens dislocation 18 years ago and had cervical hernias (C4-C7) without neurological complications. He was not taking any chronic medication and he did not have any allergies. No previous malaria history was recorded.
He was admitted under malaria suspicion. A thick blood smear revealed a 4% P. falciparum parasite count. After diagnosis, the patient was referred to the National Reference Centre, Hospital Clinic of Barcelona, during the same day. At the time of admission, he did not present with any other conditions defining severe malaria than the parasite count above 2% in a non-immune patient. On examination the patient was stable and the physical examination was normal with the exception of slight mental confusion. The patient was admitted to an intermediate care unit and intravenous artesunate was started. After the second dose (180 mg = 2.4 mg per patient kilogram per dose), 12 h after the first one, the patient started with intense coluria (coke-like colour) (Figure 1 ). Urine analyses showed no red cells but haemoglobinuria. At that time, parasitemia was 0, and parameters of haemolysis appeared, with increased levels of bilirrubin and lactate dehydrogenase (peak day 2), and reduced levels of haemoglobin and haptoglobin (Table 1) . Thus the diagnosis of intravascular haemolysis with haemoglobinuria (or blackwater fever) was established. Other causes or triggers of the haemolysis than artesunate were ruled out: serologic tests for dengue and leptospira as well as blood cultures and direct Coombs test were negative; there was no evidence of thalassemia, he had normal glucose-6 phosphate dehydrogenase activity and he did not have past history of splenectomy. Afterwards, intravenous artesunate was stopped and the treatment was switched to atovaquone-proguanil (250 mg atovaquone/100 mg proguanil per tablet, four tablets per day) for 3 more days without complications and progressive clinical recovery. The patient did not need blood transfusions or suffered of renal impairment. Two days after the beginning of the haemolytic event, clinical pneumonia was diagnosed with clinical and radiological criteria but without final microbiological diagnosis, and the patient received ceftriaxone for 5 days and levofloxacin for 10 days. Haemoglobinuria disappeared by Day 5 of admission with slow recovery of haemolytic parameters. The patient was discharged after 7 days of admission.
The patient was completely recovered after 4 weeks and no signs of delayed haemolysis were observed.
Discussion and Conclusions
Herein we have described the case of a patient with haemolytic anaemia and hemoglobinuria in the context of malaria under treatment with artesunate (blackwater fever). The acute haemolysis in our case could be due to malaria itself. Plasmodium can induce haemolytic anaemia due to the inflammatory cascade added to the rupture of erythrocytes, parasitized or not. 7 However, the fact that the haemolysis started after two doses of artesunate makes the drug suspicious of a relevant role in its development. Artesunate can induce oxidant haemolysis, although in lesser degree than quinine or mefloquine. 8 Artesunate also changes the erythrocyte membrane increasing its fragility. 8 Accordingly,
artesunate has been related to acute haemolysis with haemoglobinuria in a Cambodian patient after artesunate derivatives in an uncomplicated P. falciparum infection, 9,10 besides the previously commented description in larger studies amongst immune population in the past (AQUAMAT 4 and SEAQUAMAT
5
). Patients with splenectomy, thalassemia or low glucose-6 phosphate dehydrogenase activity have more risk to suffer severe haemolysis during Plasmodium infection, 9 although our patient did not have any known underlying condition. Other described trigger of haemolysis that our patient presented is the presence of a bacterial infection, 10 although pneumonia was diagnosed after the beginning of the haemolysis. The clinical consequences in the case described were mild but highlights the importance to monitor urine as well as haemolytic parameters in severe malaria after artesunate treatment, especially in splenectomized or thalassemic patients, in order to avoid renal impairment or severe anaemia.
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